PharmaTelevision - Will GSK’s Investment In External Research Pay Off?

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Will GSK’s Investment In External Research Pay Off?

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

As we go further into 2009 and the deals and mergers start to hot up, the question everyone wants an answer to is 'How will big pharma fill their pipelines?' Ad Rawcliffe, Senior VP WWBD and Finance at GSK, joined Fintan Walton in San Francisco to talk about the coming year and how GSK's partnering helps them to invest in science externally to compliment and strengthen their internal research.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The $2.7 billion fund and the key issues in negotiating deals with biotech companies.

Fintan Walton:

Hello and welcome to PharmaVentures business review brought to you by PharmaTelevision. We are here in San Francisco recoding a series of interviews with key companies both here in the US and from around the world. Hello and welcome to PharmaVentures business review here in San Francisco. On this show I have Adrian Rawcliffe, who is Senior Vice President of Business -- Worldwide Business Development and R&D finance at GlaxoSmithKline. Welcome to the show.

Adrian Rawcliffe:

Delighted to be here.

Fintan Walton:

And you play a key role obviously within GSK, you report to the Chairman of Research and Development, Moncef Slaoui, your responsibilities for all of the worldwide business development activities of GSK and that extends as being effectively the Finance Director for the Chairman of Research and Development at GSK which is a 2.7 billion pound budget, you sleep well at night?

Adrian Rawcliffe:

Well it is an interesting job because as well as the normal head of worldwide business development responsibilities and I've also yes got the financial management responsibilities for the R&D budget. But given the GSK's been so invested in external activities from the past decade and so much of our pipeline is externally derived then there is a certain synergy from not only doing the deals but also working out how we finance our R&D activities over the next few years.

Fintan Walton:

Right, so the key thing here is obviously is turning that 2.7 billion pounds into a productive pipeline, successful pipeline and clearly there is the internal research and the external research. So let's just look at the external research for the moment from a business development perspective, you know clearly every biotech company out there knows about GSK, and GSK would normally be on the list of companies which companies would approach. What do you see as the key issues that face GSK when it comes into trying to negotiate with deals with outside parties like biotech companies?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Adrian Rawcliffe

Senior Vice President, Worldwide Business Development

Adrian Rawcliffe, is Senior Vice President, Worldwide Business Development for GlaxoSmithKline. In this role he has global responsibility for all business-development activities. Within Worldwide Business Development, Adrian Rawcliffe leads a global team of scientific and transaction experts building diverse collaborations relating to compounds (early stage discovery programs through to marketed products) and technologies including co-development, in-licensing, product acquisition, and / or co-promotion / co-marketing arrangements, R&D based mergers & acquisitions, technology licensing, research collaborations, academic relationships, post-agreement alliance management. Adrian Rawcliffe had most recently served as Managing Partner and President, SR One Ltd, GSK's venture-capital business. Previously, he served as Vice President, Genetics and Discovery Deal Structuring, concentrating on collaborations in early-stage drug development, and Vice President, Transactions and Ventures, leading a US-based transactions team whose activities encompassed both in-licensing and out-licensing. Adrian Rawcliffe holds a BSc degree in Natural Sciences from the University of Durham, UK. He joined in 1997 from Coopers and Lybrand, where he was a Chartered Accountant involved in a range of business-advisory activities.

GlaxoSmithKline Plc

GlaxoSmithKline, is a United Kingdom -based pharmaceutical, biological, and healthcare company. It is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti- infectives, central nervous system, respiratory, gastro-intestinal, metabolic, oncology , and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. GSK was formed in 2001 by the merger of GlaxoWellcome (formed from the mergers of Burroughs Wellcome & Company and Glaxo Laboratories), and SmithKline Beecham from Beecham, and SmithKline Beckman.